Komori
Glory (6457) · FactAdvanced

Continuation of Research and Development Activities

First written in FY2017-Q1. 23 of 30 entries say "Restated". Latest entry: 2026-08-07.

30entries
11years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017-Q1 – FY2019-Q3RestatedFY2022-Q1 – FY2024-Q32016: 220162017: 320172018: 320182019: 420192020: 420202021: 420212022: 220222023: 220232024: 120242025: 220252026: 32026
Same theme, other companies
Continuation of R&D activities with no change in statusA theme 192 companies write about · 0 as a headwind · 181 as a tailwind

45 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 192 companies compared. The sentences above are computed from all 192.
Full recordFilings, disclosures and news, newest first
  1. 2026-08-07AdvancedEarnings presentation

    「R&D expenses 5,563 +7.3% 20,000 → 22,000 +12.2%」

    First-quarter R&D expenses increased 7.3% year on year, and the full-year forecast was raised from ¥20.0 billion to ¥22.0 billion.
  2. FY2026AdvancedAnnual report

    「The Company currently has 1,533 research and development staff, representing approximately 14% of Group employees, primarily at the Company. It conducts activities ranging from basic research to product development and design, and total research and development expenses for the consolidated fiscal year were ¥19,611 million, including capitalized expenses.」

    The Company disclosed 1,533 research and development staff, representing approximately 14% of Group employees, and research and development expenses of ¥19,611 million. It also described development results including a self-service cash management system, TOFREE BI, an AI camera analytics service and self-service POS systems.
  3. 2026-05-15RestatedEarnings presentation

    「R&D expenses 19,057 - 19,611 2.8% 20,000 2.0%」

    R&D expenses for the fiscal year ending March 2026 were ¥19,611 million, up 2.8% year on year, confirming the continuation of R&D activities.
  4. FY2026-H1RestatedAnnual report

    「The Group's research and development expenses for the cumulative interim period were ¥9,428 million. There were no material changes in the status of the Group's research and development activities during the cumulative interim period.」

    Research and development expenses totaled ¥942.8 million for the cumulative interim period, and there were no material changes in the status of research and development activities.
  5. FY2025AdvancedAnnual report

    「The Company currently has 1,563 research and development staff, representing approximately 14% of Group employees, primarily at the Company. It conducts activities ranging from basic research to product development and design, and total research and development expenses for the consolidated fiscal year were ¥19,935 million.」

    Research and development staff totaled 1,563, representing approximately 14% of Group employees, and research and development expenses totaled ¥19,935 million.
  6. FY2024-Q3RestatedAnnual report

    「The Group's research and development expenses for the cumulative third quarter were ¥13,886 million. There were no material changes in the status of the Group's research and development activities during the cumulative third quarter.」

    Research and development expenses totaled ¥13,886 million for the cumulative third quarter, and there were no material changes in the status of research and development activities.
  7. FY2024-Q2RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated second quarter under review was ¥8,973 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated second quarter under review.」

    Research and development expenses totaled ¥897.3 million for the cumulative second quarter, and there were no material changes in the status of research and development activities.
  8. FY2024-Q1RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated first quarter under review was ¥3,957 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated first quarter under review.」

    Research and development expenditure was ¥3,957 million for the first quarter, and the company states that there were no material changes in its research and development activities.
  9. FY2023-Q2RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated second quarter under review was ¥7,070 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated second quarter under review.」

    Cumulative research and development expenditure through the second quarter was ¥7,070 million, and the company states that there were no material changes in its research and development activities.
  10. FY2022-Q3RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated third quarter under review was ¥10,827 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated third quarter under review.」

    Cumulative research and development expenditure through the third quarter was ¥10,827 million, and the company states that there were no material changes in its research and development activities.
  11. FY2022-Q2RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated second quarter under review was ¥7,244 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated second quarter under review.」

    Cumulative research and development expenditure through the second quarter was ¥7,244 million, and the company states that there were no material changes in its research and development activities.
  12. FY2022-Q1RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated first quarter under review was ¥3,344 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated first quarter under review.」

    Research and development expenditure was ¥3,344 million for the first quarter, and the company states that there were no material changes in its research and development activities.
  13. FY2021AdvancedAnnual report

    「The Group currently has 1,247 research and development staff, centered on the company, representing approximately 12% of Group employees, and conducts activities ranging from basic research to product development and design. Total research and development expenditure for the current consolidated fiscal year was ¥14,730 million.」

    The company has 1,247 research and development staff, representing approximately 12% of Group employees, and research and development expenditure of ¥14,730 million, indicating an expansion in the scale of research and development from the previous fiscal year.
  14. FY2021-Q3RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated third quarter under review was ¥10,479 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated third quarter under review.」

    Cumulative research and development expenditure through the third quarter was ¥10,479 million, and the company states that there were no material changes in its research and development activities.
  15. FY2021-Q2RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated second quarter under review was ¥6,921 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated second quarter under review.」

    Cumulative research and development expenditure through the second quarter was ¥6,921 million, and the company states that there were no material changes in its research and development activities.
  16. FY2021-Q1RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated first quarter under review was ¥3,185 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated first quarter under review.」

    Research and development expenditure was ¥3,185 million for the first quarter, and the company states that there were no material changes in its research and development activities.
  17. FY2020AdvancedAnnual report

    「The Group currently has 1,108 research and development staff, centered on the company, representing approximately 11% of Group employees, and conducts activities ranging from basic research to product development and design. Total research and development expenditure for the current consolidated fiscal year was ¥14,082 million.」

    The company reports 1,108 research and development staff, approximately 11% of Group employees, and research and development expenditure of ¥14,082 million. This was an increase from ¥13,171 million in the previous fiscal year, and the company also reports development results including coin-wrapping machines, automated payment terminals, teller-assist machines, and facial-recognition and image-recognition AI.
  18. FY2020-Q3RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated third quarter under review was ¥10,219 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated third quarter under review.」

    Cumulative research and development expenditure through the third quarter was ¥10,219 million, and the company states that there were no material changes in its research and development activities.
  19. FY2020-Q2RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated second quarter under review was ¥6,663 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated second quarter under review.」

    Cumulative research and development expenditure through the second quarter was ¥6,663 million, and the company states that there were no material changes in its research and development activities.
  20. FY2020-Q1RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated first quarter under review was ¥3,104 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated first quarter under review.」

    Research and development expenditure was ¥3,104 million for the first quarter, and the company states that there were no material changes in its research and development activities.
  21. FY2019AdvancedAnnual report

    「The Group currently has 1,105 research and development staff, centered on the company, representing approximately 12% of Group employees, and conducts activities ranging from basic research to product development and design. Total research and development expenditure for the current consolidated fiscal year was ¥13,171 million.」

    The company reports 1,105 research and development staff, approximately 12% of Group employees, and research and development expenditure of ¥13,171 million, as well as a track record of developing new products and technologies in each market.
  22. FY2019-Q3RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated third quarter under review was ¥10,046 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated third quarter under review.」

    Cumulative research and development expenditure through the third quarter was ¥10,046 million, and the company states that there were no material changes in its research and development activities.
  23. FY2019-Q2RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated second quarter under review was ¥6,818 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated second quarter under review.」

    Cumulative research and development expenditure was ¥6,818 million, and the company states that there were no material changes in its research and development activities.
  24. FY2019-Q1RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated first quarter under review was ¥3,226 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated first quarter under review.」

    Research and development expenditure was ¥3,226 million for the quarter, and the company states that there were no material changes in its research and development activities.
  25. FY2018-Q3RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated third quarter under review was ¥10,071 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated third quarter under review.」

    Cumulative research and development expenditure was ¥10,071 million, and the company states that there were no material changes in its research and development activities.
  26. FY2018-Q2RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated second quarter under review was ¥6,833 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated second quarter under review.」

    Cumulative research and development expenditure was ¥6,833 million, and the company states that there were no material changes in its research and development activities.
  27. FY2018-Q1RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated first quarter under review was ¥3,353 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated first quarter under review.」

    Research and development expenditure was ¥3,353 million for the quarter, and the company states that there were no material changes in its research and development activities.
  28. FY2017-Q3RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated third quarter under review was ¥10,296 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated third quarter under review.」

    Cumulative research and development expenditure was ¥10,296 million, and the company states that there were no material changes in its research and development activities.
  29. FY2017-Q2RestatedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated second quarter under review was ¥6,759 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated second quarter under review.」

    Cumulative research and development expenditure was ¥6,759 million, and the company states that there were no material changes in its research and development activities.
  30. FY2017-Q1First statedAnnual report

    「The Group’s total research and development expenditure during the cumulative consolidated first quarter under review was ¥3,175 million. There were no material changes in the status of the Group’s research and development activities during the cumulative consolidated first quarter under review.」

    Research and development expenditure was ¥3,175 million for the quarter, and the company states that there were no material changes in its research and development activities.
Moved together

"Expanding the overseas business through regional strategies and direct sales and maintenance networks" moved the same way as this thread, in the same document, in 6 of its 30 moves.

644443★123456
  1. ★This thread
  2. 1Expanding the overseas business through regional strategies and direct sales and maintenance networks6×
  3. 2Improvement in Operating Income/Loss in Overseas Markets4×
  4. 3Increase in maintenance revenue4×
  5. 4Decrease in Operating Cash Flow Due to an Increase in Inventory4×
  6. 5Use of Acquired Treasury Shares for M&A and Other Purposes4×
  7. 6Strong Financial Market Sales and Earnings Growth3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Glory yet. It last moved in the Earnings presentation of 2026-08-07: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Continuation of Research and Development Activities | GLORY LTD. (6457) | Komori